Young Tak Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Young Tak Lim has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
- Eu Jeen Yang
Department of Pediatrics, Pusan National University School of Medicines, Yangsan, Korea
11 shared publications - Ye Jee Shim
Department of Pediatrics, School of Medicine Kyungpook National University Daegu Korea
9 shared publications Kyung Mi Park
Department of Pediatrics, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea
8 shared publicationsEu Jeen Yang
Department of Pediatrics, Pusan National University Children’s Hospital, Pusan National University School of Medicine, Yangsan, Korea
6 shared publications- Eun Jin Choi
Department of Pediatrics, Daegu Catholic University Medical Center, Daegu, Republic of Korea
5 shared publications - Hee Young Shin
Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea
5 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 9036
Tandem Versus Single Autologous Stem Cell Transplantation for High-Risk Neuroblastoma: A Systematic Review and Meta-Analysis
Background/Objectives: Tandem high-dose chemotherapy with autologous stem cell transplantation (ASCT) is used to intensify consolidation for high-risk neuroblastoma. One randomized trial supports it, but the wider evidence has not been synthesized quantitatively. Methods: We searched PubMed, Embase, Web of Science and Cochrane CENTRAL on 2 October 2026 for randomized and non-randomized studies comparing tandem with single ASCT for event-free survival (EFS) or overall survival (OS). The randomized trial was the main evidence. Non-randomized studies were grouped by analysis type and pooled with the trial if eligible and not at critical risk of bias. Missing hazard ratios (HRs) were derived from survival proportions and log-rank p values. Risk of bias was assessed with RoB 2 and ROBINS-I, and certainty with GRADE. Results: Of 698 records screened, five studies were included (one randomized trial, four non-randomized studies; 657 patients), and four were pooled (631 patients). In the trial, tandem ASCT improved EFS (HR 0.67, 95% CI 0.49–0.92). Eligible non-randomized studies gave a similar estimate (HR 0.65, 0.43–0.99); the pooled HR was 0.66 (0.51–0.85; I2 = 0%), about 13 more patients per 100 event-free at 3 years. The pooled HR for OS was 0.82 (0.57–1.17; two studies). EFS estimates ranged from 0.62 to 0.68 in sensitivity analyses but were attenuated after adding a registry that included relapsed and adult patients (0.82, 0.56–1.19). Certainty was moderate for EFS and low for OS. Conclusions: Tandem ASCT probably improves EFS in high-risk neuroblastoma; its effect on OS is uncertain. Whether the benefit depends on anti-GD2 immunotherapy, or persists against busulfan/melphalan, remains untested.
- 18 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 9036
Open AccessTandem Versus Single Autologous Stem Cell Transplantation for High-Risk Neuroblastoma: A Systematic Review and Meta-Analysis
Background/Objectives: Tandem high-dose chemotherapy with autologous stem cell transplantation (ASCT) is used to intensify consolidation for high-risk neuroblastoma. One randomized trial supports it, but the wider evidence has not been synthesized quantitatively. Methods: We searched PubMed, Embase, Web of Science and Cochrane CENTRAL on 2 October 2026 for randomized and non-randomized studies comparing tandem with single ASCT for event-free survival (EFS) or overall survival (OS). The randomized trial was the main evidence. Non-randomized studies were grouped by analysis type and pooled with the trial if eligible and not at critical risk of bias. Missing hazard ratios (HRs) were derived from survival proportions and log-rank p values. Risk of bias was assessed with RoB 2 and ROBINS-I, and certainty with GRADE. Results: Of 698 records screened, five studies were included (one randomized trial, four non-randomized studies; 657 patients), and four were pooled (631 patients). In the trial, tandem ASCT improved EFS (HR 0.67, 95% CI 0.49–0.92). Eligible non-randomized studies gave a similar estimate (HR 0.65, 0.43–0.99); the pooled HR was 0.66 (0.51–0.85; I2 = 0%), about 13 more patients per 100 event-free at 3 years. The pooled HR for OS was 0.82 (0.57–1.17; two studies). EFS estimates ranged from 0.62 to 0.68 in sensitivity analyses but were attenuated after adding a registry that included relapsed and adult patients (0.82, 0.56–1.19). Certainty was moderate for EFS and low for OS. Conclusions: Tandem ASCT probably improves EFS in high-risk neuroblastoma; its effect on OS is uncertain. Whether the benefit depends on anti-GD2 immunotherapy, or persists against busulfan/melphalan, remains untested.
- Open Access
- 31 October 2023
- Published by The Korean Society of Pediatric Hematology-Oncology in Clinical Pediatric Hematology-Oncology
- Vol. 30 (2) , 70-74
Lineage Switch Subsequently Developed after Isolated Extramedullary Relapse in Children with Acute Myeloid Leukemia
Yee Rae Park, Eu Jeen Yang, Ju Kyung Hyun, Ina Jeong, In-Sook Kim and Young Tak Lim. CPHO 2023;30:70-4. https://doi.org/10.15264/cpho.2023.30.2.70
- 31 October 2023
- Published by The Korean Society of Pediatric Hematology-Oncology in Clinical Pediatric Hematology-Oncology
- Vol. 30 (2) , 70-74
Open AccessLineage Switch Subsequently Developed after Isolated Extramedullary Relapse in Children with Acute Myeloid Leukemia
Yee Rae Park, Eu Jeen Yang, Ju Kyung Hyun, Ina Jeong, In-Sook Kim and Young Tak Lim. CPHO 2023;30:70-4. https://doi.org/10.15264/cpho.2023.30.2.70
- Open Access
- 15 January 2022
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 54 (1) , 269-276
Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group
Purpose Acute promyelocytic leukemia (APL) is a rare disease in children and there are some different characteristics between children and adult. We aimed to evaluate incidence, clinical characteristics and treatment outcomes of pediatric APL in Korea.Materials and Methods Seventy-nine pediatric APL patients diagnosed from January 2009 to December 2016 in 16 tertiary medical centers in Korea were reviewed retrospectively.Results Of 801 acute myeloid leukemia children, 79 (9.9%) were diagnosed with APL. The median age at diagnosis was 10.6 years (range, 1.3 to 18.0). Male and female ratio was 1:0.93. Thirty patients (38.0%) had white blood cell (WBC) count greater than 10×109/L at diagnosis. All patients received induction therapy consisting of all-trans retinoic acid and chemotherapy. Five patients (6.6%) died during induction chemotherapy and 66 patients (86.8%) achieved complete remission (CR) after induction chemotherapy. The causes of death were three intracranial hemorrhage, one cerebral infarction, and one sepsis. Five patients (7.1%) suffered a relapse during or after maintenance chemotherapy. The estimated 4-year event-free survival and overall survival (OS) rates were 82.1%±4.4%, 89.7%±5.1%, respectively. The 4-year OS was significantly higher in patients with initial WBC < 10×109/L than in those with initial WBC ≥ 10×109/L (p=0.020).Conclusion This study showed that the CR rates and survival outcomes in Korean pediatric APL patients were relatively good. The initial WBC count was the most important prognostic factor and most causes of death were related to serious bleeding in the early stage of treatment.
- 15 January 2022
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 54 (1) , 269-276
Open AccessClinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group
Purpose Acute promyelocytic leukemia (APL) is a rare disease in children and there are some different characteristics between children and adult. We aimed to evaluate incidence, clinical characteristics and treatment outcomes of pediatric APL in Korea.Materials and Methods Seventy-nine pediatric APL patients diagnosed from January 2009 to December 2016 in 16 tertiary medical centers in Korea were reviewed retrospectively.Results Of 801 acute myeloid leukemia children, 79 (9.9%) were diagnosed with APL. The median age at diagnosis was 10.6 years (range, 1.3 to 18.0). Male and female ratio was 1:0.93. Thirty patients (38.0%) had white blood cell (WBC) count greater than 10×109/L at diagnosis. All patients received induction therapy consisting of all-trans retinoic acid and chemotherapy. Five patients (6.6%) died during induction chemotherapy and 66 patients (86.8%) achieved complete remission (CR) after induction chemotherapy. The causes of death were three intracranial hemorrhage, one cerebral infarction, and one sepsis. Five patients (7.1%) suffered a relapse during or after maintenance chemotherapy. The estimated 4-year event-free survival and overall survival (OS) rates were 82.1%±4.4%, 89.7%±5.1%, respectively. The 4-year OS was significantly higher in patients with initial WBC < 10×109/L than in those with initial WBC ≥ 10×109/L (p=0.020).Conclusion This study showed that the CR rates and survival outcomes in Korean pediatric APL patients were relatively good. The initial WBC count was the most important prognostic factor and most causes of death were related to serious bleeding in the early stage of treatment.
- Open Access
Genetic Confirmation and Identification of Novel Variants for Glanzmann Thrombasthenia and Other Inherited Platelet Function Disorders: A Study by the Korean Pediatric Hematology Oncology Group (KPHOG)
The diagnosis of inherited platelet function disorders (IPFDs) is challenging owing to the unavailability of essential testing methods, including light transmission aggregometry and flow cytometry, in several medical centers in Korea. This study, conducted by the Korean Pediatric Hematology Oncology Group from March 2017 to December 2020, aimed to identify the causative genetic variants of IPFDs in Korean patients using next-generation sequencing (NGS). Targeted exome sequencing, followed by whole-genome sequencing, was performed for diagnosing IPFDs. Of the 11 unrelated patients with suspected IPFDs enrolled in this study, 10 patients and 2 of their family members were diagnosed with Glanzmann thrombasthenia (GT). The variant c.1913+5G>T of ITGB3 was the most common, followed by c.2333A>C (p.Gln778Pro) of ITGB2B. Known variants of GT, including c.917A>C (p.His306Pro) of ITGB3 and c.2975del (p.Glu992Glyfs*), c.257T>C (p.Leu86Pro), and c.1750C>T (p.Arg584*) of ITGA2B, were identified. Four novel variants of GT, c.1451G>T (p.Gly484Val) and c.1595G>T (p.Cys532Phe) of ITGB3 and c.1184G>T (p.Gly395Val) and c.2390del (p.Gly797Valfs*29) of ITGA2B, were revealed. The remaining patient was diagnosed with platelet type bleeding disorder 18 and harbored two novel RASGRP2 variants, c.1479dup (p.Arg494Alafs*54) and c.813+1G>A. We demonstrated the successful application of NGS for the accurate and differential diagnosis of heterogeneous IPFDs.
Open AccessGenetic Confirmation and Identification of Novel Variants for Glanzmann Thrombasthenia and Other Inherited Platelet Function Disorders: A Study by the Korean Pediatric Hematology Oncology Group (KPHOG)
The diagnosis of inherited platelet function disorders (IPFDs) is challenging owing to the unavailability of essential testing methods, including light transmission aggregometry and flow cytometry, in several medical centers in Korea. This study, conducted by the Korean Pediatric Hematology Oncology Group from March 2017 to December 2020, aimed to identify the causative genetic variants of IPFDs in Korean patients using next-generation sequencing (NGS). Targeted exome sequencing, followed by whole-genome sequencing, was performed for diagnosing IPFDs. Of the 11 unrelated patients with suspected IPFDs enrolled in this study, 10 patients and 2 of their family members were diagnosed with Glanzmann thrombasthenia (GT). The variant c.1913+5G>T of ITGB3 was the most common, followed by c.2333A>C (p.Gln778Pro) of ITGB2B. Known variants of GT, including c.917A>C (p.His306Pro) of ITGB3 and c.2975del (p.Glu992Glyfs*), c.257T>C (p.Leu86Pro), and c.1750C>T (p.Arg584*) of ITGA2B, were identified. Four novel variants of GT, c.1451G>T (p.Gly484Val) and c.1595G>T (p.Cys532Phe) of ITGB3 and c.1184G>T (p.Gly395Val) and c.2390del (p.Gly797Valfs*29) of ITGA2B, were revealed. The remaining patient was diagnosed with platelet type bleeding disorder 18 and harbored two novel RASGRP2 variants, c.1479dup (p.Arg494Alafs*54) and c.813+1G>A. We demonstrated the successful application of NGS for the accurate and differential diagnosis of heterogeneous IPFDs.
- Open Access
Treatment Outcomes of Pediatric Acute Myeloid Leukemia in the Yeungnam Region: A Multicenter Retrospective Study of the Study Alliance of Yeungnam Pediatric Hematology–Oncology (SAYPH)
Acute myeloid leukemia (AML) is the second most common pediatric leukemia, with a survival rate of 70%. In this retrospective study, we evaluated the treatment outcomes of pediatric AML among 144 patients diagnosed between 2000 and 2013. After induction, 80.6% of patients achieved complete remission (CR). The 5-year overall survival (OS) and event-free survival (EFS) rates were 58.8 ± 4.2% and 49.8 ± 4.2%, respectively. Based on the response to induction therapy, the 5-year OS was 66.9 ± 5.7% in patients with CR (p < 0.001). Ninety-nine patients with CR after induction therapy were examined, and their 5-year OS and EFS were 66.4 ± 4.9% and 56.3 ± 5.1%, respectively. The 5-year OS rates according to treatment were 59.9 ± 7.4% in the chemotherapy group and 72.3 ± 6.3% in the hematopoietic stem cell transplantation (HSCT) group (p = 0.089). The EFS was 50.1 ± 7.4% in the chemotherapy group and 61.7 ± 6.9% in the HSCT group (p = 0.098). OS and EFS according to cytogenetics were insignificant. Our findings confirmed that the response to induction treatment was important for survival and HSCT had no significant survival benefits compared with those of chemotherapy. Moreover, many early induction deaths under the age of 2 years were observed.
Open AccessTreatment Outcomes of Pediatric Acute Myeloid Leukemia in the Yeungnam Region: A Multicenter Retrospective Study of the Study Alliance of Yeungnam Pediatric Hematology–Oncology (SAYPH)
Acute myeloid leukemia (AML) is the second most common pediatric leukemia, with a survival rate of 70%. In this retrospective study, we evaluated the treatment outcomes of pediatric AML among 144 patients diagnosed between 2000 and 2013. After induction, 80.6% of patients achieved complete remission (CR). The 5-year overall survival (OS) and event-free survival (EFS) rates were 58.8 ± 4.2% and 49.8 ± 4.2%, respectively. Based on the response to induction therapy, the 5-year OS was 66.9 ± 5.7% in patients with CR (p < 0.001). Ninety-nine patients with CR after induction therapy were examined, and their 5-year OS and EFS were 66.4 ± 4.9% and 56.3 ± 5.1%, respectively. The 5-year OS rates according to treatment were 59.9 ± 7.4% in the chemotherapy group and 72.3 ± 6.3% in the hematopoietic stem cell transplantation (HSCT) group (p = 0.089). The EFS was 50.1 ± 7.4% in the chemotherapy group and 61.7 ± 6.9% in the HSCT group (p = 0.098). OS and EFS according to cytogenetics were insignificant. Our findings confirmed that the response to induction treatment was important for survival and HSCT had no significant survival benefits compared with those of chemotherapy. Moreover, many early induction deaths under the age of 2 years were observed.
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (4) , e37
Erratum: Correction of Affiliations in the Article “Clinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma: a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study”
Lee JM, et al. J Korean Med Sci. 2021 Jan;36(4):e37. https://doi.org/10.3346/jkms.2021.36.e37
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (4) , e37
Open AccessErratum: Correction of Affiliations in the Article “Clinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma: a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study”
Lee JM, et al. J Korean Med Sci. 2021 Jan;36(4):e37. https://doi.org/10.3346/jkms.2021.36.e37
- 3 March 2020
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 42 (4) , 275-280
Treatment Outcome in Pediatric Acute Lymphoblastic Leukemia With Hyperleukocytosis in the Yeungnam Region of Korea: A Multicenter Retrospective Study
Acute lymphoblastic leukemia (ALL) with hyperleukocytosis at diagnosis is associated with early morbidity and mortality due to complications of leukostasis. Of 535 pediatric ALL patients (January 2004 to December 2016 from the Yeungnam region of Korea), 72 (13.5%) patients with an initial white blood cell (WBC) count of ≥100×109/L were included in this study, of whom 38 patients had extreme hyperleukocytosis (WBC>200×109/L) at diagnosis. Fourteen patients (19.4%) had ≥1 early respiratory and neurologic complications during induction therapy. Relapse occurred in 8 patients (24.2%) with extreme hyperleukocytosis and in 1 patient (3.0%) with an initial WBC count of 100 to 200×109/L (P=0.012). Estimated 10-year event-free survival rate (EFS) and overall survival rate were 78.3%±8.4% and 82.6%±7.7%, respectively. The 10-year EFS was significantly lower in patients with an initial WBC count of >200×109/L than in those with an initial WBC count of 100 to 200×109/L (65.7%±13.4% vs. 91.2%±7.9%; P=0.011). The 10-year EFS and overall survival rate did not differ significantly between patients with extreme hyperleukocytosis who received hematopoietic stem cell transplantation and those who received chemotherapy. In conclusion, pediatric ALL with hyperleukocytosis can lead to early complications and mortality. Patients with initial extreme hyperleukocytosis showed significantly poorer prognosis than those with WBC counts of 100 to 200×109/L.
- 3 March 2020
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 42 (4) , 275-280
Treatment Outcome in Pediatric Acute Lymphoblastic Leukemia With Hyperleukocytosis in the Yeungnam Region of Korea: A Multicenter Retrospective Study
Acute lymphoblastic leukemia (ALL) with hyperleukocytosis at diagnosis is associated with early morbidity and mortality due to complications of leukostasis. Of 535 pediatric ALL patients (January 2004 to December 2016 from the Yeungnam region of Korea), 72 (13.5%) patients with an initial white blood cell (WBC) count of ≥100×109/L were included in this study, of whom 38 patients had extreme hyperleukocytosis (WBC>200×109/L) at diagnosis. Fourteen patients (19.4%) had ≥1 early respiratory and neurologic complications during induction therapy. Relapse occurred in 8 patients (24.2%) with extreme hyperleukocytosis and in 1 patient (3.0%) with an initial WBC count of 100 to 200×109/L (P=0.012). Estimated 10-year event-free survival rate (EFS) and overall survival rate were 78.3%±8.4% and 82.6%±7.7%, respectively. The 10-year EFS was significantly lower in patients with an initial WBC count of >200×109/L than in those with an initial WBC count of 100 to 200×109/L (65.7%±13.4% vs. 91.2%±7.9%; P=0.011). The 10-year EFS and overall survival rate did not differ significantly between patients with extreme hyperleukocytosis who received hematopoietic stem cell transplantation and those who received chemotherapy. In conclusion, pediatric ALL with hyperleukocytosis can lead to early complications and mortality. Patients with initial extreme hyperleukocytosis showed significantly poorer prognosis than those with WBC counts of 100 to 200×109/L.
- Open Access
- 1 January 2020
- Published by XMLink in Journal of Korean Medical Science
- Vol. 35 (46) , e393
Clinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma: a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study
Lee JM, et al. J Korean Med Sci. 2020 Oct;35(46):e393. https://doi.org/10.3346/jkms.2020.35.e393
- 1 January 2020
- Published by XMLink in Journal of Korean Medical Science
- Vol. 35 (46) , e393
Open AccessClinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma: a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study
Lee JM, et al. J Korean Med Sci. 2020 Oct;35(46):e393. https://doi.org/10.3346/jkms.2020.35.e393
- Open Access
- 1 January 2020
- Published by XMLink in Journal of Korean Medical Science
- Vol. 35 (33) , e279
Epidemiological Study of Hereditary Hemolytic Anemia in the Korean Pediatric Population during 1997–2016: a Nationwide Retrospective Cohort Study
Shim YJ, et al. J Korean Med Sci. 2020 Jul;35(33):e279. https://doi.org/10.3346/jkms.2020.35.e279
- 1 January 2020
- Published by XMLink in Journal of Korean Medical Science
- Vol. 35 (33) , e279
Open AccessEpidemiological Study of Hereditary Hemolytic Anemia in the Korean Pediatric Population during 1997–2016: a Nationwide Retrospective Cohort Study
Shim YJ, et al. J Korean Med Sci. 2020 Jul;35(33):e279. https://doi.org/10.3346/jkms.2020.35.e279
- 18 December 2019
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 37 (2) , 129-139
Mutation analysis in Korean patients with T-cell acute lymphoblastic leukemia
Genomic studies have illuminated the alterations in pathways underlying T-cell acute lymphoblastic leukemia (T-ALL) pathogenesis, but detailed mutation data by next-generation sequencing have not been reported in Korean patients. We aimed to investigate mutation frequency, spectrum, and pattern in the Korean patients with T-ALL. We designed a multigene panel targeting 101 genes and validated it using 10 reference materials. The mutation analysis was done in a total of 10 patients with T-ALL. Clinical data and laboratory tests including immunophenotyping, cytogenetics, and molecular genetic tests were also investigated. All of the 10 patients harbored at least one mutation (range 1–6 per patient). A total of 34 clinically significant mutations including 15 novel mutations were identified in 23 genes. The median of variant allelic frequencies (VAFs) and blasts were counted upto 33% (range 5–91%) and 79% (range 38–90%), respectively. Recurrent mutations were involved in epigenetic regulators (60%), NOTCH1 signaling (40%), PI3K-AKT (40%), JAK-STAT (30%), and transcription factors (30%). We found that both NOTCH signaling and JAK-STAT signaling were positively associated with epigenetic regulators, while showed mutually exclusive patterns with PI3K-AKT pathway. This study showed that the frequency of mutations in epigenetic regulators in Korean patients was significantly higher than expected. Distribution of VAF as well as mutation spectrum is considerably heterogeneous in Korean patients with T-ALL. Although from a limited number of patients, this study provides the first detailed mutational portrait of T-ALL of Korean patients, and gives additional insight into molecular pathogenesis of the disease.
- 18 December 2019
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 37 (2) , 129-139
Mutation analysis in Korean patients with T-cell acute lymphoblastic leukemia
Genomic studies have illuminated the alterations in pathways underlying T-cell acute lymphoblastic leukemia (T-ALL) pathogenesis, but detailed mutation data by next-generation sequencing have not been reported in Korean patients. We aimed to investigate mutation frequency, spectrum, and pattern in the Korean patients with T-ALL. We designed a multigene panel targeting 101 genes and validated it using 10 reference materials. The mutation analysis was done in a total of 10 patients with T-ALL. Clinical data and laboratory tests including immunophenotyping, cytogenetics, and molecular genetic tests were also investigated. All of the 10 patients harbored at least one mutation (range 1–6 per patient). A total of 34 clinically significant mutations including 15 novel mutations were identified in 23 genes. The median of variant allelic frequencies (VAFs) and blasts were counted upto 33% (range 5–91%) and 79% (range 38–90%), respectively. Recurrent mutations were involved in epigenetic regulators (60%), NOTCH1 signaling (40%), PI3K-AKT (40%), JAK-STAT (30%), and transcription factors (30%). We found that both NOTCH signaling and JAK-STAT signaling were positively associated with epigenetic regulators, while showed mutually exclusive patterns with PI3K-AKT pathway. This study showed that the frequency of mutations in epigenetic regulators in Korean patients was significantly higher than expected. Distribution of VAF as well as mutation spectrum is considerably heterogeneous in Korean patients with T-ALL. Although from a limited number of patients, this study provides the first detailed mutational portrait of T-ALL of Korean patients, and gives additional insight into molecular pathogenesis of the disease.